---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-098346"
form_type: "8-K"
ticker: "HSCS"
cik: "0001468492"
company_name: "HeartSciences Inc."
filed_at: "2025-07-24T23:59:59+00:00"
generated_at: "2026-05-18T02:12:02.677328+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# HeartSciences reports no FY2025 revenue, $1.1M cash; advances MyoVista platform

## Summary
- Zero revenue for fiscal year ended April 30, 2025; cash and equivalents $1.1M, shareholders' equity $0.2M.
- Raised $3.1M gross in Reg A+ offering post-year-end; converted $0.9M debt to equity.
- Launched MyoVista Insights cloud software platform in May 2025 at early adopter sites.
- MyoVista wavECG device nearing FDA 510(k) submission; CMS approved $128/test reimbursement for AI-ECG algorithms.
- FDA Breakthrough Device designation for aortic stenosis algorithm; 44 granted patents worldwide.

## SEC filing metadata
- accession: 0000950170-25-098346
- form_type: 8-K
- ticker: HSCS
- cik: 0001468492
- company_name: HeartSciences Inc.
- filed_at: 2025-07-24T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468492/000095017025098346/0000950170-25-098346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468492/000095017025098346/hscs-20250724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-098346
- JSON: https://secwatch.observer/filing/0000950170-25-098346.json
- Plain text: https://secwatch.observer/filing/0000950170-25-098346.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.